Pfizer, Inc.
PFE
Jodie situation report
Pfizer, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 32 directly disclosed connections are confirming.
- Acquired in-process R&D expenses increased $128 million in Q1 2026 reflecting upfront and milestone payments on certain in‑licensing agreements.
Invalidation: The isolated read changes if PFE's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind PFE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ARVNArvinas, Inc.partnerMay 5, 2026 ▾
“37 Approvals: PRODUCT INDICATION DATE/MARKET Veppanu (vepdegestrant) (a) Treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endo…”
ABBVAbbVie Inc.partnerFeb 26, 2026 ▾
“The U.S.”
Depended on by
ODTX17.5% of ODTXcustomerJun 17, 2026 ▾
“The Company recognized $ 0.4 million of revenue associated with the Pfizer MTA during the three months ended March 31, 2025, which is included in collaboration revenue on the condensed consolidated statements of operations and comprehensive loss.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 34 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PFE is currently a Follower in the organic co-movement group Drug Manufacturers - General. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.